冠心病并左心功能不全患者利用曲美他嗪治疗的疗效及药理机制分析  

Curative effect of trimetazidine in the treatment of coronary heart disease complicated with left heart insufficiency patients and its pharmacological mechanism analysis

作　　者：徐福建[1] XU Fu-fian.(Department of Pharmacy,Shangdong Province Heze Municiple Hospital, Heze 274000, Chin)

机构地区：[1]山东省菏泽市立医院药学部,274000

出　　处：《中国实用医药》2017年第7期27-29,共3页China Practical Medicine

摘　　要：目的探讨曲美他嗪治疗冠心病并左心功能不全的临床疗效,并分析其药理机制。方法 80例冠心病并左心功能不全患者,随机分为对照组和观察组,各40例。对照组采用常规疗法,观察组在对照组基础上加用曲美他嗪治疗,比较两组临床疗效。结果对照组再住院率为22.5%,死亡率为15.0%,高于观察组的5.0%、2.5%,差异有统计学意义(P<0.05)。观察组心功能Ⅱ级占72.5%,高于对照组32.5%,差异有统计学意义(P<0.05)。两组治疗前左室舒张末内径(LVEDD)、左室射血分数(LVEF)、超敏C反应蛋白(hs-CRP)及血清脑钠肽(BNP)比较差异无统计学意义(P>0.05);治疗后两组上述指标均明显优于本组治疗前,且观察组均明显优于对照组,差异有统计学意义(P<0.05)。结论曲美他嗪治疗冠心病并左心功能不全患者效果优良,可明显改善患者心功能,降低再住院率与死亡率,改善预后,进而改善患者生存质量,值得推广。Objective To explore the clinical curative effect of trimetazidine in the treatment of coronary heart disease complicated with left heart insufficiency patients and analyze its pharmacological mechanism. Methods A total of 80 coronary heart disease complicated with left heart insufficiency patients were randomly divided into control group and observation group, with 40 cases in each group. The control group received conventional methods, and the observation group received trimetazidine on the basis of the control group for treatment. Clinical curative effect was compared in two groups. Results The control group had rehospitalization rate as 22.5%, death rate as 15.0%, which were all higher than 5.0% and 2.5% in the observation group, and the difference had statistical significance （P〈0.05）. The observation group had higher cardiac function grade Ⅱ rate as 72.5% than 32.5% in the control group, and the difference had statistical significance （P〈0.05）. Both groups had no statistically significant difference in left ventricular end-diastolic diameter （LVEDD）, left ventricular ejection fraction （LVEF）, hypersensitive c-reactive protein （hs-CRP） and serum brain natriuretic peptide （BNP） before treatment between two groups （P〉0.05）. After treatment both groups had better above indicators than before treatment, and the observation group had obviously better indicators than the control group, and the difference had statistical significance （P〈0.05）. Conclusion Trimetazidine shows excellent effect for the treatment of coronary heart disease complicated with left heart insufficiency patients, which can significantly improves cardiac function in patients, reduce hospitalization rate and mortality rate, improve prognosis, and thus improving the quality of survival. So it is worth promoting.

关 键 词：冠心病 左心功能不全 曲美他嗪 

分 类 号：R541.4[医药卫生—心血管疾病]